In the News
PPD inks deal with China’s HLT to create data science-driven research solutions
The partnership will focus on data-driven feasibility, patient recruitment and real-world evidence offerings for both global and China-based pharma and biotech companies.
Regulatory reforms in Australia – Improving access to new medicines
Peter Lynch discusses regulatory changes in Australia that are designed to lead to earlier access to lifesaving medicines for patients.
Proactive regulatory intelligence communication
Kirsten Messmer outlines regulatory intelligence communication approaches for medium to large companies and highlights the advantages and disadvantages of each.
PPD beefing up biologics lab services in Ireland
PPD expanding its biologics capabilities in Athlone to include cell and gene therapy analytical testing.
PPD Expands GMP Lab Testing Capabilities
PPD Laboratories is focused on providing cutting-edge gene and cell therapy analytical testing services and capabilities around the world.
PPD adds biologics testing to GMP lineup in Ireland
The company’s goal is to offer the same extensive biologic, gene and cell therapy portfolio to clients in both Europe and North America.
Osteoporosis: Addressing the unmet need
Rose Blackburne and Davide Garrisi provide an overview of the osteoporosis landscape and the associated regulatory environment.
Planning and execution
In this article from PPD and PPD-SNBL, the authors discuss key factors to consider when developing a pharmacovigilance presence in Japan.
Trend: R&D modeling and simulation
Evidera’s Anuraag Kansal discusses the impact computer simulation has on the understanding of and hypotheses around a clinical trial.
